REMAP-CAP results

REMAP-CAP results


Equivalency of Tocilizumab and Sarilumab

The REMAP-CAP investigators are pleased to share additional results from the COVID-19 Immune Modulation Domain.

Previously, an adaptive analysis revealed that within the COVID-19 Immune Modulation Domain both tocilizumab and sarilumab had reached platform conclusions for efficacy when compared to the ‘no immune modulation’ intervention. As a result, the ‘no immune modulation’ intervention was closed, and the COVID-19 Immune Modulation Domain continued as a comparison between available active interventions (anakinra, interferon-β1a, tocilizumab, and sarilumab). Since this time, more than 900 additional participants have been randomised to this domain.

The results of the most recent adaptive analysis, communicated to the REMAP-CAP International Trial Steering Committee by the DSMB, indicate that tocilizumab and sarilumab have now reached the pre-specified statistical trigger for equivalence.

These results provide a clear indication that tocilizumab and sarilumab are equally effective for the treatment of patients with severe COVID-19, and are also the most effective interventions included in this domain. The REMAP-CAP ITSC have therefore decided to pause recruitment to this domain. A full analysis of all interventions included in this domain, including anakinra and interferon-β1a, will be completed and the results made available as soon as possible.

Please visit their website for more information.

Visit website